Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT00580320 Completed - Melanoma Clinical Trials

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Start date: September 2004
Phase: Phase 1
Study type: Interventional

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.

NCT ID: NCT00576680 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This research study will test the safety of RAD001 in combination with temozolomide.

NCT ID: NCT00510068 Completed - Clinical trials for Advanced Neuroendocrine Tumors of Pancreatic Origin

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

RADIANT-3
Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.

NCT ID: NCT00501540 Completed - Clinical trials for Neuroendocrine Tumors

Lithium for Low-Grade Neuroendocrine Tumors

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn more about the effectiveness and side effects of lithium treatment for subjects with low-grade neuroendocrine tumors.

NCT ID: NCT00454363 Completed - Clinical trials for Pancreatic Polypeptide Tumor

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00442533 Completed - Clinical trials for Neuroendocrine Tumors

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Start date: August 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.

NCT ID: NCT00434109 Completed - Clinical trials for Neuroendocrine Tumor

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.

NCT ID: NCT00428220 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Start date: July 2007
Phase: N/A
Study type: Interventional

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

NCT ID: NCT00427349 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Start date: November 7, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

NCT ID: NCT00424723 Completed - Clinical trials for Neuroendocrine Tumors

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.